IMMUNOTHERAPY Benefit with anti-PD-L1

被引：2
|
作者：
Romero, Diana
机构：
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2017年 / 14卷 / 02期
关键词：
D O I：
10.1038/nrclinonc.2016.218
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [41] Enhancing Tumor Immunotherapy by Multivalent Anti-PD-L1 Nanobody Assembled via Ferritin Nanocage
    Liu, Manman
    Jin, Duo
    Yu, Wenxin
    Yu, Jiaji
    Cao, Kaiming
    Cheng, Junjie
    Zheng, Xiaohu
    Wang, Andrew
    Liu, Yangzhong
    ADVANCED SCIENCE, 2024, 11 (20)
  • [42] Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
    Delaney, Nicolas
    Michot, Jean-Marie
    Comont, Thibault
    Kramkimel, Nora
    Lazarovici, Julien
    Dupont, Romain
    Champiat, Stephane
    Chahine, Claude
    Robert, Caroline
    Herbaux, Charles
    Besse, Benjamin
    Guillemin, Aude
    Mateus, Christine
    Pautier, Patricia
    Saiag, Purippe
    Madonna, Enmauela
    Maerevoet, Marie
    Bout, Jeao-Christophe
    Leduc, Charlotte
    Biscay, Pascal
    Quere, Gilles
    Nardin, Charlee
    Ebbo, Mikael
    Albiges, Laurence
    Marret, Gregoire
    Levrat, Virginie
    Dujon, Cecile
    Vargaftig, Jacques
    Laghouati, Salim
    Croisille, Loure
    Voisin, Anne-Laure
    Godeau, Bertrand
    Massard, Christophe
    Ribrag, Vincent
    Marabelle, Aurellen
    Michel, Marc
    Lambotte, Olivier
    LANCET HAEMATOLOGY, 2019, 6 (01): : E48 - E57
  • [43] Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis
    Wu, Jinyao
    Chen, Yaokun
    Chen, Lingzhi
    Ji, Zeqi
    Tian, Huiting
    Zheng, Daitian
    Yang, Qiuping
    Liu, Yiyuan
    Cai, Jiehui
    Zheng, Jiehua
    Chen, Yexi
    Li, Zhiyang
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [44] Evaluation of anti-PD-L1 and anti-VEGF-A combinatorial immunotherapy in preclinical murine liver cancer models
    Kam, Shing
    Ramadori, Pierluigi
    Fan, Chaofan
    Sagar, Sagar
    Heikenwalder, Mathias
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
  • [45] Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
    Puccini, Alberto
    Battaglin, Francesca
    Iaia, Maria Laura
    Lenz, Heinz-Josef
    Salem, Mohamed E.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [46] Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy
    Swaika, Abhisek
    Hammond, William A.
    Joseph, Richard W.
    MOLECULAR IMMUNOLOGY, 2015, 67 (02) : 4 - 17
  • [47] Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models
    Wang, Sarah
    Sun, Kaiming
    Xiao, Yonghong
    Feng, Bin
    Mikule, Keith
    Ramaswamy, Sridhar
    Hanke, Jeffrey
    Wang, Jing
    CANCER RESEARCH, 2018, 78 (13)
  • [48] New insights into the anti-PD-L1 and anti-PD-1 reagents in cancer therapy
    Chen, Cheng
    Huang, Jian-An
    EUROPEAN JOURNAL OF INFLAMMATION, 2016, 14 (01) : 61 - 65
  • [49] Anti-PD-L1 inhibitor durvalumab in bladder cancer
    Brower, Vicki
    LANCET ONCOLOGY, 2016, 17 (07): : E275 - E275
  • [50] Pulmonary Sarcoidosis Associated With Anti-Pd-L1 Therapy
    Balestra, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
12345